The firms will use miRNA-based cell characterization workflows and technologies to develop panels for human MSC products and cell banks, and said that the collaboration "furthers the identification" of miRNA biomarkers across a wide range of donors that may predict hMSC performance. They anticipate offering their customers access to each other's technologies "to enhance the quality, performance, and therapeutic knowledge of MSC technology."
The end goal of the collaboration is to eliminate the functional variability that is inherent in current MSC technology and to accelerate the use of stem cells as a technology, Sistemic and RoosterBio said.
Financial and other terms of the agreement were not disclosed.
"Thorough characterization of hMSC products and cell banks is central to creating a stable, robust technology that can be simply and affordably deployed across a range of applications," RoosterBio Chief Executive Jon Rowley said in a statement. "RoosterBio's rich library of MSC donors married with Sistemic's miRNA characterization platform will provide both predictive biomarkers and critical quality attributes that will allow MSC technology to reach its full potential."